(145 days)
Not Found
No
The device description explicitly states it uses a simple algorithm to calculate a qSOFA score based on three predefined criteria and thresholds. There is no mention of learning, training data, or complex models typically associated with AI/ML.
No
Explanation: The device is intended to monitor patient data and calculate a qSOFA score to indicate risk; it is explicitly stated that it is not intended for making clinical decisions regarding patient treatment or for diagnostic purposes. Therefore, it is not a therapeutic device.
No
The "Intended Use / Indications for Use" section explicitly states, "NAVOYCDS is not intended for making clinical decisions regarding patient treatment or for diagnostic purposes."
Yes
The device description outlines software modules (gateway, qSOFA score module, web-based dashboard) and a workflow that involves receiving, processing, and presenting data. There is no mention of any hardware components being part of the device itself, only that it receives data from "already cleared patient monitoring devices." The performance testing focuses on system-level tests, software life-cycle processes, usability, and cybersecurity, consistent with a software-only device.
Based on the provided information, NAVOYCDS is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for diagnostic purposes.
- NAVOYCDS Function: NAVOYCDS uses patient data already collected by other cleared patient monitoring devices (respiratory rate, blood pressure, GCS). It does not collect or analyze specimens from the human body.
- Intended Use: The intended use explicitly states that NAVOYCDS is "not intended for making clinical decisions regarding patient treatment or for diagnostic purposes." Its purpose is to calculate a score based on existing data to identify patients at greater risk for a poor outcome, serving as an adjunct to monitoring.
Therefore, NAVOYCDS falls outside the scope of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
NAVOYCDS is intended to be used with patient data from already cleared patient monitoring devices which measure respiratory rate, systolic blood pressure, and Glasgow Coma Scale (GCS) in adult patients being monitored in a healthcare facility. The device uses an algorithm to calculate a qSOF A score (also known as quickSOFA) which indicates adult patients with suspected infection who are at greater risk for a poor outcome. It uses three criteria, assigning one point for low blood pressure (SBP ≤100 mmHg), high respiratory rate (≥22 breaths per min), or altered mentation (Glasgow coma scale
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: a seal on the left and the FDA acronym with the full name of the agency on the right. The seal features a stylized depiction of human services, while the text part includes the acronym "FDA" in a blue square, followed by "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
July 22, 2024
AlgoDx AB Andreas Macura 0A PO Box 559173-7985, Visiting address: Gotgatan 22A Stockholm, 106 31 Sweden
Re: K240558
Trade/Device Name: Navoycds Regulation Number: 21 CFR 870.2300 Regulation Name: Cardiac Monitor (Including Cardiotachometer And Rate Alarm) Regulatory Class: Class II Product Code: PLB Dated: February 28, 2024 Received: February 28, 2024
Dear Andreas Macura:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Robert T. Kazmierski -S
for
LCDR Stephen Browning Assistant Director DHT2A: Division of Cardiac Electrophysiology, Diagnostics
2
and Monitoring Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K240558
Device Name NAVOYCDS
Indications for Use (Describe)
NAVOYCDS is intended to be used with patient data from already cleared patient monitoring devices which measure respiratory rate, systolic blood pressure, and Glasgow Coma Scale (GCS) in adult patients being monitored in a healthcare facility. The device uses an algorithm to calculate a qSOF A score (also known as quickSOFA) which indicates adult patients with suspected infection who are at greater risk for a poor outcome. It uses three criteria, assigning one point for low blood pressure (SBP ≤100 mmHg), high respiratory rate (≥22 breaths per min), or altered mentation (Glasgow coma scale Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Contact Details
21 CFR 807.92(a)(1)
| Applicant Name | AlgoDx AB |
|---|---|
| Applicant Address | PO Box 559173-7985, Visiting address: Götgatan 22A |
| Stockholm 106 31 Sweden | |
| Applicant Contact | |
| Telephone | +46768668842 |
| Applicant Contact | Mr. Andreas Macura |
| Applicant Contact Email | andreas.macura@algodx.com |
Device Name
| 21CFR 807.92(a)(2) | |
|---|---|
| Device Trade Name | NAVOYCDS |
| Common Name | Cardiac monitor (including cardiotachometer and rate |
| alarm) | |
| Classification Name | Multivariate Vital Signs Index |
| Regulation Number | 870.2300 |
| Product Code(s) | PLB |
Legally Marketed Predicate Devices
21 CFR 807.92(a)(3)
| Predicate # | K230386 |
|---|---|
| Predicate Trade Name | |
| (Primary Predicate is listed | |
| first) | SpassageQ |
| Product Code | PLB |
Device Description Summary
21 CFR 807.92(a)(4)
NAVOYCDS consists of:
• A gateway module for handling clinical data supporting the HL7 format FHIR.
• A qSOFA score module to calculate patients' qSOFA scores and offer their last 72 hours history data.
· A web-based dashboard to render patients' qSOFA scores in a visually distinctive way depending on their value and enable intended users to view patients with suspected infection.
The NAVOYCDS system works in the following sequence:
- · Receive patient data from the HL7 gateway system.
- · Extract 3 vital signs from the patient data and store them in the database.
5
· The Glasgow Coma Scale (GCS) of a patient is stored in the database when a user submits it.
· NAVOYCDS calculates the qSOFA score automatically and stores the result in the database.
· NAVOYCDS delivers 3 vital signs. gSOFA score, GCS to users.
· The qSOFA score is presented in a visually distinctive way depending on the value and enables users to view patients with suspected infection.
Interpretation of qSOFA score:
The qSOFA score (also known as quickSOFA) is a bedside prompt that may identify patients with suspected infection who are at greater risk for a poor outcome. It uses three
criteria, assigning one point for low blood pressure (SBP ≤100 mmHg), high respiratory
rate (≥22 breaths per min), or altered mentation (Glasgow coma scale